The US president has announced a new deal that would lower the price of some weight loss medications

A representative of pharmaceutical industry collapsed in the Oval Office on Thursday as members of US President Donald Trump's administration were announcing a new deal for weight-loss medications.

The man was standing behind Trump during the event when his knees appeared to suddenly buckle underneath him. According to media outlets, he was initially identified as Novo Nordisk executive Gordon Finlay. The company produces Ozempic, Rybelsus, and Wegovy. Novo Nordisk, however, later denied that it was Finlay.

According to Fox News reporter Jacqui Heinrich, who witnessed the incident firsthand, Dr. Mehmet Oz, the administrator of the Centers for Medicare and Medicaid Services, assisted the executive as he collapsed, ensuring that he did not hit his head when he fell. Cabinet members attended to the man, propping up his legs, after reporters were escorted out of the Oval Office.

White House Press Secretary Karoline Leavitt later said that "the gentleman is okay".

Earlier in the Oval Office, Trump announced that prices of weight loss drugs like Ozempic would be "much lower". The press conference featured executives from Novo Nordisk and another drug maker, Eli Lilly, which have worked with the administration on a deal to make weight loss medications, known as GLP-1s, more affordable.

Drugmakers will broaden access to popular obesity drugs like Ozempic, Wegovy, and Zepbound through TrumpRx, a new government website launching next year. Oral versions could start at $149 a month once cleared by the FDA. Injectable GLP-1 drugs will cost $245 a month for Medicare and Medicaid patients using them for approved conditions such as diabetes.

(RT.com)